Editors:
- From humble beginnings over 25 years ago as a lipid kinase activity associated with certain oncoproteins, PI3K (phosphoinositide 3-kinase) has been catapulted to the forefront of drug development in cancer, immunity and thrombosis, with the first clinical trials of PI3K pathway inhibitors now in progress.
Part of the book series: Current Topics in Microbiology and Immunology (CT MICROBIOLOGY, volume 347)
Buy it now
Buying options
Tax calculation will be finalised at checkout
Other ways to access
This is a preview of subscription content, log in via an institution to check for access.
Table of contents (13 chapters)
-
Front Matter
-
Back Matter
About this book
Editors and Affiliations
-
Intellikine, La Jolla, USA
Christian Rommel
-
, Institute of Cancer and the London Schoo, Queen Mary, University of London, London, United Kingdom
Bart Vanhaesebroeck
-
, Dept. Molecular & Exp. Medicine, Scripps Research Institute, La Jolla, USA
Peter K. Vogt
Bibliographic Information
Book Title: Phosphoinositide 3-kinase in Health and Disease
Book Subtitle: Volume 2
Editors: Christian Rommel, Bart Vanhaesebroeck, Peter K. Vogt
Series Title: Current Topics in Microbiology and Immunology
DOI: https://doi.org/10.1007/978-3-642-14816-3
Publisher: Springer Berlin, Heidelberg
eBook Packages: Biomedical and Life Sciences, Biomedical and Life Sciences (R0)
Copyright Information: The Editor(s) (if applicable) and The Author(s), under exclusive license to Springer-Verlag GmbH, DE, part of Springer Nature 2011
Hardcover ISBN: 978-3-642-14815-6Published: 01 October 2010
Softcover ISBN: 978-3-642-26530-3Published: 03 December 2012
eBook ISBN: 978-3-642-14816-3Published: 17 October 2010
Series ISSN: 0070-217X
Series E-ISSN: 2196-9965
Edition Number: 1
Number of Pages: X, 306
Number of Illustrations: 33 b/w illustrations, 46 illustrations in colour
Topics: Cancer Research